Tisotumab (poeder)

Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin. Tisotumab (powder) can be used for the research of solid tumors[1][2].

1418628-81-5

Anti-Human F3 Recombinant Antibody (powder)

12352203

ADC Antibody

Antibody-drug Conjugate/ADC Related

Cancer

[Tisotumab(powder)]

(144.66 kDa)

[1]Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22 (5) :609-619. |[2]Takao S, et al. Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies. Cancer Immunol Immunother. 2025 Jan 3;74 (2) :48.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P99271A/

Inhibitory Antibodies

No Development Reported